[
  {
    "ts": null,
    "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
    "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747237080,
      "headline": "BlackRock Health Sciences Opportunities Fund Q1 2025 Commentary",
      "id": 134453013,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "BlackRock Health Sciences Opportunities Fund posted returns of 3.66% (Institutional shares) and 3.60% (Investor A shares, without sales charge) for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=a09fa1031198fe3423a5318e0d47459c521efb03ae4196a089069f85176f0e54"
    }
  },
  {
    "ts": null,
    "headline": "Are Boston Scientific Corporation (NYSE:BSX) Investors Paying Above The Intrinsic Value?",
    "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Boston Scientific fair value estimate is US$78.80 Current...",
    "url": "https://finnhub.io/api/news?id=3247fb1062ff94b9d68838eb446a7820bc977c1a06613fbff6e4a48bcf729a86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747227614,
      "headline": "Are Boston Scientific Corporation (NYSE:BSX) Investors Paying Above The Intrinsic Value?",
      "id": 134460993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Boston Scientific fair value estimate is US$78.80 Current...",
      "url": "https://finnhub.io/api/news?id=3247fb1062ff94b9d68838eb446a7820bc977c1a06613fbff6e4a48bcf729a86"
    }
  },
  {
    "ts": null,
    "headline": "Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?",
    "summary": "Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.",
    "url": "https://finnhub.io/api/news?id=3d6a4bbe425e01d2a17ead77c4a394a8f2813a758c148664ae75a9336e5ba929",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747221060,
      "headline": "Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?",
      "id": 134460994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.",
      "url": "https://finnhub.io/api/news?id=3d6a4bbe425e01d2a17ead77c4a394a8f2813a758c148664ae75a9336e5ba929"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Growth Equity Fund Q1 2025 Commentary",
    "summary": "Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell 1000 Growth Indexâs -9.97%.",
    "url": "https://finnhub.io/api/news?id=18c9bbc6b81692bfba93830d77b86454e725fe7091cfd4064d5b67663954fbde",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747212240,
      "headline": "Parnassus Growth Equity Fund Q1 2025 Commentary",
      "id": 134435565,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166679764/image_2166679764.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell 1000 Growth Indexâs -9.97%.",
      "url": "https://finnhub.io/api/news?id=18c9bbc6b81692bfba93830d77b86454e725fe7091cfd4064d5b67663954fbde"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Global Impact Fund Q1 2025 Commentary",
    "summary": "The Hartford Global Impact Fund (I Share) outperformed the MSCI ACWI Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=2b71041fce234f403899e6b2b7556c5b2fce8103e275b2884515cf74b32bbcd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747184280,
      "headline": "Hartford Global Impact Fund Q1 2025 Commentary",
      "id": 134431611,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1817128859/image_1817128859.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "The Hartford Global Impact Fund (I Share) outperformed the MSCI ACWI Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=2b71041fce234f403899e6b2b7556c5b2fce8103e275b2884515cf74b32bbcd2"
    }
  }
]